In randomised, placebo-controlled clinical trials, filgrastim did not increase the incidence of undesirable effects associated with cytotoxic chemotherapy.
En ensayos clínicos randomizados controlados con placebo, filgrastim no incremento la incidencia de reacciones adversas asociados a quimioterapia citotóxica.